Eyeworld Daily News

33 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 celebration of their distinguished ca- reers and contributions. The exhibit will be available for viewing during the meeting. EW the U.S. Food and Drug Adminis- tration (FDA) in the late 1970s to investigate the use of the neurotoxin in humans with the same condition. Dr. Scott formed his own manufac- turing firm to produce Oculinum, as he called the drug, and proceeded to inject patients with strabismus using EMG-guided injection, which he developed as a means of not only delivering Oculinum but recording the activity of the muscle in which the needle was inserted. After reporting his success- ful clinical findings to the FDA in 1980, Dr. Scott trained hundreds of ophthalmologists in the injection of Oculinum. In 1989, the FDA approved the use of the drug for both strabismus and blepharospasm. In 1991, Allergan bought Oculinum and renamed the drug Botox. In addition to its ophthalmic uses, Botox effectively treats a variety of ailments, from muscle spasms in the face, neck, shoulder, vocal cords and bladder, to excessive sweating and debilitating migraine headaches. But it was during its original ophthal- mic applications that its cosmetic use was accidentally discovered; the neurotoxin that paralyzed the extraocular muscles drastically reduced—at least temporarily—the appearance of frown lines and crow's feet around the eyes. Dr. Scott became director of the Smith-Kettlewell Eye Research In- stitute in 1982 and remained in the position until 2004. He also served as vice chair of ophthalmology at California Pacific Medical Center from 1997 to 2006. He is currently a senior scientist at the Strabismus Research Foundation. Dr. Scott has published dozens of articles and papers and is the recipient of numer- ous honors and awards, including the Linksz Medal (International Strabismus Association), the Proctor Medal (Association for Vision and Research in Ophthalmology), the Parks Silver Medal (American Asso- ciation for Pediatric Ophthalmol- ogy and Strabismus), the Lifetime Achievement Award (International Toxin Association), and the Senior Award (American Academy of Oph- thalmology). Dr. Scott received his medical degree at the University of California San Francisco School of Medicine. He completed his intern- ship at the University of Minnesota Hospital and Clinic, and residen- cies at the University of Minnesota Hospital and Clinic (neurological surgery) and Stanford University Medical Center (ophthalmology). The ASCRS Hall of Fame was created in 1999 to honor pioneers such as these with an ongoing I N T R O D U C I N G HAPPINESS IN SIGHT New PROKERA ® Clear helps heal the cornea and maintains visual acuity PROKERA ® Clear goes beyond hydration to: Rejuvenate the cornea Simultaneously reduce inflammation and promote quality healing Treat chronic dry eye cases DEWS level 2, as well as levels 3 and 4 NEW See us at ASCRS Booth 1717 SM-267, Rev 2, 4/5/2016

• Cover